Chronic Pain Syndrome: When Pain Becomes a Disease

What Chronic Pain Syndrome Actually Is

There’s a critical difference between having chronic pain and having chronic pain syndrome. Both involve pain that persists beyond the expected healing time, typically defined as longer than three months. But chronic pain syndrome is a more complex, more disabling condition in which pain is accompanied by significant changes in mood, sleep, cognition, and daily function, and where these changes have become interlocked in a cycle that perpetuates itself.

The ICD-11 added “chronic primary pain” as a standalone diagnosis in 2019, recognizing what pain researchers had known for years: in some patients, pain becomes the disease itself rather than a symptom of something else [1]. This isn’t semantic wordplay. It has real treatment implications. If you’re treating only the joint, or only the back, or only the nerve, you’re missing most of the problem.

How Pain Becomes a Syndrome

The Neuroscience of Central Sensitization

When pain signals persistently bombard the spinal cord and brain, the system does not passively receive them. It adapts, and often not in a helpful way. Neurons in the dorsal horn of the spinal cord become more excitable, responding to lighter stimuli and firing more readily. This is called peripheral sensitization. When the changes extend into the central nervous system, it becomes central sensitization [2].

In someone with central sensitization, several things happen. Normal touch can become painful (allodynia). Painful stimuli cause more pain than they should (hyperalgesia). Pain spreads beyond the original injury site. And areas of the brain involved in pain processing, the anterior cingulate cortex, the insula, the prefrontal cortex, show structural and functional changes visible on neuroimaging [3].

The descending pain modulation system, which normally acts as a brake on incoming pain signals, also weakens. The brainstem structures that release endogenous opioids, serotonin, and norepinephrine to suppress pain signals become less effective. Pain begets more pain through mechanisms that have nothing to do with ongoing tissue damage.

The Role of Neuroinflammation

Research over the past decade has identified neuroinflammation as a key driver of chronic pain syndrome. Activated microglia, the brain’s immune cells, release pro-inflammatory cytokines that sensitize pain pathways and contribute to the mood and cognitive symptoms that often accompany CPS [4]. This explains, at least partly, why conditions like fibromyalgia and CRPS involve widespread symptoms that go far beyond any single injury site.

Elevated levels of inflammatory markers including TNF-alpha, IL-6, and IL-1beta have been found in cerebrospinal fluid and blood in patients with fibromyalgia and other chronic pain conditions. This is a biological finding, not a psychological one.

The Psychological-Biological Feedback Loop

Chronic pain reliably produces depression, anxiety, and sleep disturbance. This isn’t weakness or an overreaction. The same brain circuits that process pain overlap significantly with those that regulate mood and stress responses. Persistent activation of pain circuits alters the HPA axis stress response, depletes dopamine in reward circuits, and disrupts sleep architecture, all of which, in turn, lower the threshold for pain perception [5].

This is why chronic pain syndrome is so much harder to treat than simple chronic pain. The depression isn’t just a reaction to pain; it actively amplifies it. The sleep disruption isn’t just unpleasant; it increases central sensitization. Each component worsens the others.

Who Develops Chronic Pain Syndrome

Not everyone with an injury or painful condition develops CPS. Several factors increase the risk.

Biological Factors

Genetic variations affecting serotonin and dopamine neurotransmission, as well as variants in genes regulating COMT (catechol-O-methyltransferase), influence how sensitized the nervous system becomes in response to pain [6]. People with a family history of chronic pain conditions are at higher risk, as are those with pre-existing sleep disorders.

Psychological Factors

Pain catastrophizing, the tendency to ruminate on pain, magnify its threat, and feel helpless, is one of the strongest predictors of who develops chronic pain syndrome following an injury. This is not a personality flaw. Pain catastrophizing reflects nervous system hypervigilance that can be specifically targeted and reduced with appropriate therapy. A history of trauma or adverse childhood experiences also significantly increases CPS risk, likely through long-term effects on HPA axis regulation and stress reactivity [7].

Social and Contextual Factors

Being involved in litigation over an injury, job dissatisfaction, and social isolation all increase the likelihood that acute pain transitions to CPS. These are not reasons to dismiss the pain. They are modifiable factors that a comprehensive treatment plan should address.

Diagnosing Chronic Pain Syndrome

There’s no blood test for CPS, which leads to underdiagnosis and, sometimes, dismissal. Clinicians who understand the condition use a combination of clinical history, validated questionnaires, and sometimes quantitative sensory testing (QST) to assess the degree of central sensitization present.

The Central Sensitization Inventory (CSI) is a validated 25-item questionnaire that can help identify central sensitization and differentiate CPS from purely peripheral pain conditions [8]. Pressure pain threshold testing, where a calibrated device measures the pressure at which stimulation becomes painful, can quantify hyperalgesia and track it over time.

Functional MRI has demonstrated characteristic patterns of altered connectivity in pain networks in fibromyalgia and other CPS conditions, though this remains primarily a research tool rather than a clinical diagnostic test.

Treatment Approaches Specific to Chronic Pain Syndrome

Targeting Central Sensitization Directly

Duloxetine and milnacipran (SNRIs) work in part by enhancing descending pain inhibition through serotonin and norepinephrine. Pregabalin and gabapentin reduce neuronal excitability by binding to calcium channels on hyperexcitable neurons. Low-dose naltrexone (LDN) at doses around 1 to 4.5mg has shown anti-neuroinflammatory effects through its action on microglial toll-like receptors, with promising early evidence for fibromyalgia and other central sensitization conditions [9].

Ketamine Infusions

Ketamine’s NMDA receptor antagonism directly interrupts the long-term potentiation in spinal cord neurons that underlies central sensitization. A series of ketamine infusions can essentially “reset” sensitized pain circuits in some patients, providing relief that extends weeks to months beyond the infusions themselves [10]. This is one of the more mechanism-targeted treatments available for CPS, and it’s most appropriate for patients with clear central sensitization components, including those with complex regional pain syndrome, fibromyalgia, or chronic pain following surgery.

Transcranial Magnetic Stimulation and Neurofeedback

Repetitive TMS applied to the motor cortex or dorsolateral prefrontal cortex modulates activity in pain-processing and pain-modulation networks. Multiple sham-controlled trials have found significant reductions in chronic pain with rTMS, including for fibromyalgia and neuropathic pain [11]. The effects appear to outlast the stimulation period, suggesting lasting neuroplastic changes.

Neurofeedback takes a different approach, training patients to voluntarily alter their own EEG patterns using real-time feedback. Protocols targeting theta and alpha brainwave activity have shown reductions in pain intensity and improvements in sleep quality in small trials for fibromyalgia and chronic regional pain [12]. The mechanism involves strengthening inhibitory circuits and normalizing the hyperaroused pain networks characteristic of CPS.

Psychological Treatments

Pain neuroscience education (PNE) is an intervention that specifically teaches patients about central sensitization and the biology underlying their experience. A systematic review found that PNE reduces pain catastrophizing, improves physical functioning, and decreases pain intensity, with effects that persist at follow-up [13]. The mechanism is partly cognitive (changing unhelpful beliefs that amplify pain) and partly neurobiological (reducing the threat value of pain signals, which directly affects how the nervous system processes them).

Acceptance and Commitment Therapy (ACT) for chronic pain focuses on reducing avoidance of pain-related activities and building psychological flexibility. Unlike traditional CBT, ACT doesn’t aim primarily to reduce pain but to reduce the suffering and disability associated with it. Randomized trials have shown meaningful improvements in function and quality of life, and these gains hold up at long-term follow-up.

Regenerative Approaches in Chronic Pain Syndrome

Where CPS involves an identifiable structural driver, such as joint degeneration, ligament laxity, or nerve entrapment, regenerative therapies can address the peripheral pain generator that feeds the central sensitization. Removing or reducing the peripheral input doesn’t automatically reverse central sensitization, but it can significantly reduce the burden on sensitized pain circuits and make other treatments more effective.

Platelet-rich plasma for knee osteoarthritis, prolotherapy for ligamentous laxity, and shockwave therapy for chronic tendinopathies have all shown efficacy in reducing pain from the peripheral sources that may have initiated the sensitization process. In practice, combining these peripheral treatments with centrally-targeted approaches like ketamine or TMS gives many CPS patients their best chance of meaningful improvement.

BPC-157 has demonstrated the ability to reduce neuroinflammation and promote healing in neural tissue in preclinical studies, suggesting a potential role in addressing both the peripheral and central components of chronic pain syndrome, though clinical trials are needed to confirm these effects in humans.

Living With and Recovering From Chronic Pain Syndrome

Recovery from CPS is real and it happens. It typically isn’t fast, and it rarely looks like returning to zero pain. More often it looks like steadily rebuilding function, reducing pain’s interference with life, and gradually reversing the central sensitization that has accumulated over months or years. Pacing, graded activity, and sleep optimization are foundational. Sleep deprivation is one of the most potent amplifiers of central sensitization, and addressing it aggressively, whether through medication, CBT for insomnia, or sleep hygiene changes, pays dividends across all other treatments.

The trajectory of CPS is not fixed. The same neuroplasticity that allowed the nervous system to sensitize itself is also what allows it to normalize, given the right inputs over enough time.

Related Reading

• Chronic Pain Treatment: A Complete Guide to Evidence-Based Options
• Neuropathic Pain Treatment: From Medications to Regenerative Approaches
• Pain Management Without Opioids: Safer Alternatives That Work
• Fibromyalgia Treatment: Evidence-Based Options
• Ketamine Infusion Therapy for Pain and Depression
• Transcranial Magnetic Stimulation (TMS) Therapy
• Low-Dose Naltrexone: Uses and Evidence

References

1. Treede RD, Rief W, Barke A, et al. “Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11).” Pain. 2019;160(1):19-27. doi:10.1097/j.pain.0000000000001384
2. Woolf CJ. “Central sensitization: Implications for the diagnosis and treatment of pain.” Pain. 2011;152(3 Suppl):S2-15. doi:10.1016/j.pain.2010.09.030
3. Smallwood RF, Laird AR, Ramage AE, et al. “Structural brain anomalies and chronic pain: a quantitative meta-analysis of gray matter volume.” J Pain. 2013;14(7):663-675. doi:10.1016/j.jpain.2013.03.001
4. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. “Neuroinflammation and Central Sensitization in Chronic and Widespread Pain.” Anesthesiology. 2018;129(2):343-366. doi:10.1097/ALN.0000000000002130
5. Finan PH, Smith MT. “The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism.” Sleep Med Rev. 2013;17(3):173-183. doi:10.1016/j.smrv.2012.03.003
6. Diatchenko L, Slade GD, Nackley AG, et al. “Genetic basis for individual variations in pain perception and the development of a chronic pain condition.” Hum Mol Genet. 2005;14(1):135-143. doi:10.1093/hmg/ddi013
7. Tesarz J, Eich W, Treede RD, Gerhardt A. “Altered pressure pain thresholds and increased wind-up in adult patients with chronic back pain with a history of childhood maltreatment: a quantitative sensory testing study.” Pain. 2016;157(8):1799-1809. doi:10.1097/j.pain.0000000000000586
8. Mayer TG, Neblett R, Cohen H, et al. “The development and psychometric validation of the central sensitization inventory.” Pain Pract. 2012;12(4):276-285. doi:10.1111/j.1533-2500.2011.00493.x
9. Younger J, Noor N, McCue R, Mackey S. “Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.” Arthritis Rheum. 2013;65(2):529-538. doi:10.1002/art.37734
10. Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. “Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Anesth Analg. 2019;129(1):241-254. doi:10.1213/ANE.0000000000004185
11. Lefaucheur JP, Aleman A, Baeken C, et al. “Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018).” Clin Neurophysiol. 2020;131(2):474-528. doi:10.1016/j.clinph.2019.11.002
12. Jensen MP, Sherlin LH, Hakiman S, Fregni F. “Neuromodulatory approaches for chronic pain management: research findings and clinical implications.” J Neurother. 2009;13(4):196-213. doi:10.1080/10874200903334371
13. Louw A, Zimney K, Puentedura EJ, Diener I. “The efficacy of pain neuroscience education on musculoskeletal pain: A systematic review of the literature.” Physiother Theory Pract. 2016;32(5):332-355. doi:10.1080/09593985.2016.1194646